Metabolic and endocrine effects of metformin and metformin plus cyclic medroxyprogesterone acetate in women with polycystic ovary syndrome

International Journal of Gynecology and Obstetrics

Volumn 105, Issue 1, 2009, Pages 32-35

  Haydardedeoglu, Bulent ^a   Simsek, Erhan ^a   Kilicdag, Esra B ^a   Bagis, Tayfun ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

Medroxyprogesterone acetate; Metformin; Polycystic ovary syndrome

Indexed keywords

CHOLESTEROL; HOMOCYSTEINE; MEDROXYPROGESTERONE ACETATE; METFORMIN;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INSULIN RESISTANCE; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 62649100131     PISSN: 00207292     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijgo.2008.11.039     Document Type: Article

References (30)

1. Franks S. Polycystic ovary syndrome. N Engl J Med 333 13 (1995) 853-861
2. Nestler J.E. Role of obesity and insulin in the development of anovulation. In: Filicori M., and Flamigni C. (Eds). Ovulation induction: basic science and clinical advances (1994), Elsevier, Amsterdam 103-114
3. Wild R.A. Long-term health consequences of PCOS. Hum Reprod Update 8 3 (2002) 231-241
4. Pillay O.C., Te Fong L.F., Crow J.C., Benjamin E., Mould T., Atiomo W., et al. The association between polycystic ovaries and endometrial cancer. Hum Reprod 21 4 (2006) 924-929
5. Escalante Pulido J.M., and Alpizar Salazar M. Changes in insulin sensitivity, secretion and glucose effectiveness during menstrual cycle. Arch Med Res 30 1 (1999) 19-22
6. Kahn H.S., Curtis K.M., and Marchbanks P.A. Effects of injectable or implantable progestin-only contraceptives on insulin-glucose metabolism and diabetes risk. Diabetes Care 26 1 (2003) 216-225
7. The ESHRE Capri Workshop Group. Noncontraceptive health benefits of combined oral contraception. Hum Reprod Update 11 5 (2005) 513-525
8. Baillargeon J.P., McClish D.K., Essah P.A., and Nestler J.E. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab 90 7 (2005) 3863-3870
9. Virbiková J., and Cibula D. Combined oral contraceptives in the treatment of polycystic ovary syndrome. Hum Reprod Update 11 3 (2005) 277-291
10. Rewers M., Zaccaro D., D'Agostino R., Haffner S., Saad M.F., Selby J.V., et al. Insulin Resistance Atherosclerosis Study Investigators. Insulin sensitivity, insulinemia, and coronary artery disease: the Insulin Resistance Atherosclerosis Study. Diabetes Care 27 3 (2004) 781-787
11. Lorenz L.B., and Wild R.A. Polycystic ovarian syndrome: An evidence-based approach to evaluation and management of diabetes and cardiovascular risks for today's clinician. Clin Obstet Gynecol 50 1 (2007) 226-243
12. Cibula D., Fanta M., Vrbikova J., Stanicka S., Dvorakova K., Hill M., et al. The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Hum Reprod 20 1 (2005) 180-184
13. Nestler J.E. Should patients with polycystic ovarian syndrome be treated with metformin? An enthusiastic endorsement. Hum Reprod 17 8 (2002) 1950-1953
14. Bagis T., Gokcel A., Zeyneloglu H.B., Tarim E., Ki{dotless}li{dotless}cdag E.B., and Haydardedeoglu B. The effects of short-term medroxyprogesterone acetate and micronized progesterone on glucose metabolism and lipid profiles in patients with polycystic ovary syndrome: a prospective randomized study. J Clin Endocrinol Metab 87 10 (2002) 4536-4540
15. The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19 1 (2004) 41-47
16. Ferriman D., and Gallwey J.D. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 21 11 (1961) 1440-1447
17. Friedewald W.T., Levy R.J., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 6 (1972) 499-502
18. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.I. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 7 (1985) 412-419
19. Lord J.M., Flight I.H., and Norman R.J. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev 3 (2003) CD003053
20. Legro R.S., Barnhart H.X., Schlaff W.D., Carr B.R., Diamond M.P., Carson S.A., et al. Clomiphene, metformin, or both for infertility in polycystic ovary syndrome. N Engl J Med 356 6 (2007) 551-566
21. Palomba S., Falbo A., Russo T., Manguso F., Tolino A., Zullo F., et al. Insulin sensitivity after metformin suspension in normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 92 8 (2007) 3128-3135
22. Sites C.K., L'Hommedieu G.D., Toth M.J., Brochu M., Cooper B.C., and Fairhurst P.A. The effect of hormone replacement therapy on body composition, body fat distribution, and insulin sensitivity in menopausal women: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 90 5 (2005) 2701-2707
23. O'Sullivan A.J., and Ho K.K. A comparison of the effects of oral and transdermal estrogen replacement on insulin sensitivity in postmenopausal women. J Clin Endocrinol Metab 80 6 (1995) 1783-1788
24. Cagnacci A., Soldani R., Carriero P.L., Paoletti A.M., Fioretti P., and Melis G.B. Effects of low doses of transdermal 17β-estradiol on carbohydrate metabolism in postmenopausal women. J Clin Endocrinol Metab 74 6 (1992) 1396-1400
25. Fiad T.M., Cunningham S.K., and McKenna T.J. Role of progesterone deficiency in the development of luteinizing hormone and androgen abnormalities in polycystic ovary syndrome. Eur J Endocrinol 135 3 (1996) 335-339
26. Anttila L., Koskinen P., Erkkola R., Irjala K., and Ruutiainen K. Serum testosterone, androstenedione and luteinizing hormone levels after short-term medroxyprogesterone acetate treatment in women with polycystic ovarian disease. Acta Obstet Gynecol Scand 73 8 (1994) 634-636
27. Melo N.R., Latrilha M.C., Santos R.D., Pompei L.M., and Maranhão R.C. Effects in post-menopausal women of transdermal estrogen associated with progestin upon the removal from the plasma of a microemulsion that resembles low-density lipoprotein (LDL). Maturitas 50 4 (2005) 275-281
28. Fonseca V., Guba S.C., and Fink L.M. Hyperhomocysteinemia and the endocrine system: implications for atherosclerosis and thrombosis. Endocr Rev 20 5 (1999) 738-759
29. Kilicdag E.B., Bagis T., Zeyneloglu H.B., Tarim E., Aslan E., Haydardedeoglu B., et al. Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study. Hum Reprod 20 4 (2005) 894-899
30. Kilicdag E.B., Bagis T., Tarim E., Aslan E., Erkanli S., Simsek E., et al. Administration of B-group vitamins reduces circulating homocysteine in polycystic ovarian syndrome patients treated with metformin: a randomized trial. Hum Reprod 20 6 (2005) 1521-1528